The structural modeling of the interaction between levofloxacin and the mycobacterium tuberculosis gyrase catalytic site sheds light on the mechanisms of fluoroquinolones resistant tuberculosis in colombian clinical isolates

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Alvarez, N ^a,b   Zapata, E ^a,b   Mejia G I ^a,b   Realpe, T ^a,b   Araque, P ^c   Pelaez C ^d   Rouzaud, F ^a,e   Robledo, J ^a,b  

^a Corporación Para Investigaciones Biológicas ^*  (Colombia)

^b UNIVERSIDAD PONTIFICIA BOLIVARIANA   (Colombia)

^c UNIVERSIDAD EIA   (Colombia)

^d UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^e Equal Opportunity Life Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN;

ACID BASE BALANCE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; ENZYME ACTIVE SITE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MODEL; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; AMINO ACID SUBSTITUTION; CHEMISTRY; COLOMBIA; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MALE; MISSENSE MUTATION; MOLECULAR DOCKING; MULTIDRUG RESISTANCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; X RAY CRYSTALLOGRAPHY;

AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CATALYTIC DOMAIN; COLOMBIA; CRYSTALLOGRAPHY, X-RAY; DNA GYRASE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; LEVOFLOXACIN; MALE; MOLECULAR DOCKING SIMULATION; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84901265789     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/367268     Document Type: Article

References (47)

1. WHO, Global Tuberculosis Report 2012 Geneva, Switzerland World Health Organization
2. Nunn P., The global control of tuberculosis: what are the prospects? Scandinavian Journal of Infectious Diseases 2001 33 5 329 332 2-s2.0-0034966760 10.1080/003655401750173887 (Pubitemid 32573980)
3. WHO, Framework for Effective Tuberculosis Control 1994 Geneva, Switzerland World Health Organization
4. Kochi A., Tuberculosis control- Is dots the health breakthrough of the 1990s? World Health Forum 1997 18 3-4 225 232 2-s2.0-0031422087
5. Keshavjee S., Farmer P. E., Tuberculosis, drug resistance and the history of modern medicine. The New England Journal of Medicine 2012 367 931 936
6. Villarino M. E., Geiter L. J., Simone P. M., The multidrug-resistant tuberculosis challenge to public health efforts to control tuberculosis. Public Health Reports 1992 107 6 616 625 2-s2.0-0026452677
7. Mdluli K., Ma Z., Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infectious Disorders-Drug Targets 2007 7 2 1 10
8. Hegde S. S., Vetting M. W., Roderick S. L., Mitchenall L. A., Maxwell A., Takiff H. E., Blanchard J. S., A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science 2005 308 5727 1480 1483 2-s2.0-20344367084 10.1126/science.1110699 (Pubitemid 40791304)
9. 'Donnell M. R. O., Saukkonen J. J., Longo D. L., Fauci A. S., Kasper D. L., Hauser S. L., Jameson J. L., Loscalzo J., Antimycobacterial agents. Harrison's Principles of Internal Medicine New York, NY, USA McGraw-Hill. 2012, http://www.accessmedicine.com/content.aspx?aID=9122997
10. Centers for Disease Control and Prevention (CDC), Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. Morbidity and Mortality Weekly Report 2006 55 11 301 305
11. Pierre-Audigier C., Gicquel B., The contribution of molecular biology in diagnosing tuberculosis and detecting antibiotic resistance. 2012, http://www.moleculartb.org/gb/pdf/doc/Revue.pdf
12. Huang Y. Y., Deng J. Y., Gu J., Zhang Z. P., Maxwell A., Bi L. J., Chen Y. Y., Zhou Y. F., Yu Z. N., Zhang X. E., The key DNA-binding residues in the C-terminal domain of Mycobacterium tuberculosis DNA gyrase A subunit (GyrA). Nucleic Acids Research 2006 34 19 5650 5659 2-s2.0-33750996164 10.1093/nar/gkl695 (Pubitemid 44742452)
13. da Cunha E. F. F., Barbosa E. F., Oliveira A. A., Ramalho T. C., Molecular modeling of Mycobacterium tuberculosis DNA gyrase and its molecular docking study with gatifloxacin inhibitors. Journal of Biomolecular Structure and Dynamics 2010 27 5 1 6 2-s2.0-76749106664
14. Minovski N., Vračko M., Šolmajer T., Quantitative structure-activity relationship study of antitubercular fluoroquinolones. Molecular Diversity 2011 15 2 417 426 2-s2.0-80051553414 10.1007/s11030-010- 9238-5
15. Sekiguchi J. I., Miyoshi-Akiyama T., Augustynowicz-Kopeć E., Zwolska Z., Kirikae F., Toyota E., Kobayashi I., Morita K., Kudo K., Kato S., Kuratsuji T., Mori T., Kirikae T., Detection of multidrug resistance in Mycobacterium tuberculosis. Journal of Clinical Microbiology 2007 45 1 179 192 2-s2.0-33846201165 10.1128/JCM.00750-06 (Pubitemid 46106425)
16. Kim H., Nakajima C., Kim Y. U., Yokoyama K., Suzuki Y., Influence of lineage-specific amino acid dimorphisms in GyrA on Mycobacterium tuberculosis resistance to fluoroquinolones. Japanese Journal of Infectious Diseases 2012 65 1 72 74 2-s2.0-84856364913
17. Pantel A., Petrella S., Veziris N., Brossier F., Bastian S., Jarlier V., Mayer C., Aubry A., Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrobial Agents and Chemotherapy 2012 56 4 1990 1996 2-s2.0-84858690634 10.1128/AAC.06272-11
18. Zhanel G. G., Fontaine S., Adam H., Schurek K., Mayer M., Noreddin A. M., Gin A. S., Rubinstein E., Hoban D. J., A review of new fluoroquinolones: focus on their use in respiratory tract infections. Treatments in Respiratory Medicine 2006 5 6 437 465 2-s2.0-33845791463 10.2165/00151829-200605060-00009 (Pubitemid 46001331)
19. Fish D. N., Chow A. T., The clinical pharmacokinetics of levofloxacin. Clinical Pharmacokinetics 1997 32 2 101 119 2-s2.0-0031055732 (Pubitemid 27104410)
20. Garzón M. C., Angée D. Y., Llerena C., Vigilancia de la resistencia del Mycobacterium tuberculosis a los fármacos antituberculosos, Colombia 2004-2005. Biomédica 2008 28 319 326
21. Departamento Administrativo Nacional de Estadística (DANE). Encuesta Nacional de Ingresos y Gastos 2006-2007. 2012. http://www.dane.gov.co
22. Dirección Seccional de Salud y Protección Social de Antioquia. Boletín información para la acción (BIA), 2012
23. Antioquia Gobernment. 2012, http://www.antioquia.gov.co
24. Robledo J. A., Mejía G. I., Morcillo N., Chacón L., Camacho M., Luna J., Zurita J., Bodon A., Velasco M., Palomino J. C., Martin A., Portaels F., Evaluation of a rapid culture method for tuberculosis diagnosis: a Latin American multi-center study. International Journal of Tuberculosis and Lung Disease 2006 10 6 613 619 2-s2.0-33744930346 (Pubitemid 43845021)
25. CLSI,. Susceptibility testing of Mycobacteria, Nocardiae and other aerobic Actinomycetes, Approved Standard-Second edition. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, Pa, USA, 2011
26. van Soolingen D., de Haas P. E. W., Hermans P. W. M., van Embden J. D. A., DNA fingerprinting of Mycobacterium tuberculosis. Methods in Enzymology 1994 235 196 205 2-s2.0-0028303325 10.1016/0076-6879(94)35141-4
27. Springer B., Lucke K., Calligaris-Maibach R., Ritter C., Böttger E. C., Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. Journal of Clinical Microbiology 2009 47 6 1773 1780 2-s2.0-66749172966 10.1128/JCM.02501-08
28. Dewar M. J. S., Zoebisch E. G., Healy E. F., Stewart J. J. P., AM1: a new general purpose quantum mechanical molecular model. Journal of the American Chemical Society 1985 107 13 3902 3909 2-s2.0-0842341771
29. Gandhi N. R., Nunn P., Dheda K., Schaaf H. S., Zignol M., van Soolingen D., Jensen P., Bayona J., Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. The Lancet 2010 375 9728 1830 1843 2-s2.0-77952542701 10.1016/S0140-6736(10)60410-2
30. Sandgren A., Strong M., Muthukrishnan P., Weiner B. K., Church G. M., Murray M. B., Tuberculosis drug resistance mutation database. PLoS Medicine 2009 6 2 0132 0136 2-s2.0-61449239026 10.1371/journal.pmed.1000002 e1000002
31. Dalhoff A., Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdisciplinary Perspectives on Infectious Diseases 2012 1 37
32. Bhatti N., Chronos N., White J. P., Larson E., A case of resistant tuberculosis. Tubercle 1990 71 2 141 143 2-s2.0-0025277586 10.1016/0041-3879(90) 90012-W (Pubitemid 20188202)
33. Chiang C. Y., Schaaf H. S., Management of drug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease 2010 14 6 672 682 2-s2.0-77952350886
34. Dalton T., Cegielski P., Akksilp S., Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. The Lancet 2012 380 1406 1417
35. Nosova E., Bukatina A., Isaeva Y., Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacteriumtuberculosis to levofloxacin, moxifloxacin and gatifloxacin. Journal of Medical Microbiology 2012 62 108 113
36. Ritacco V., Lopéz B., Ambroggi M., HIV infection and geographically bound transmission of drug-resistant tuberculosis, Argentina. Emerging Infectious Diseases 2012 18 11 1802 1810
37. Takiff H. E., Salazar L., Guerrero C., Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrobial Agents and Chemotherapy 1994 38 4 773 780 2-s2.0-0028299121 (Pubitemid 24114017)
38. von Groll A., Martin A., Jureen P., Hoffner S., Vandamme P., Portaels F., Palomino J. C., Da Silva P. A., Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrobial Agents and Chemotherapy 2009 53 10 4498 4500 2-s2.0-70349318563 10.1128/AAC.00287-09
39. Zhang Y., Telenti A., Hatfull G. F., Jacobs W. R. Jr., Genetics of drug resistance in Mycobacterium tuberculosis. Molecular Genetics of Mycobacteria 2000 Washington, DC, USA ASM Press 235 254
40. Suzuki Y., Nakajima C., Tamaru A., Kim H., Matsuba T., Saito H., Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance. International Journal of Antimicrobial Agents 2012 39 5 435 439 2-s2.0-84859429544 10.1016/j.ijantimicag.2012.01.007
41. Shi R., Zhang J., Li C., Kazumi Y., Sugawara I., Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. Journal of Clinical Microbiology 2006 44 12 4566 4568 2-s2.0-33845583280 10.1128/JCM.01916-06 (Pubitemid 44937098)
42. Pitaksajjakul P., Wongwit W., Punprasit W., Eampokalap B., Peacock S., Ramasoota P., Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand. The Southeast Asian Journal of Tropical Medicine and Public Health 2005 36 228 237 2-s2.0-33646199504
43. Pasca M. R., Guglierame P., Arcesi F., Bellinzoni M., de Rossi E., Riccardi G., Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 2004 48 8 3175 3178 2-s2.0-3342927606 10.1128/AAC.48.8.3175-3178.2004 (Pubitemid 38989198)
44. Kam K. M., Yip C. W., Cheung T. L., Tang H. S., Leung O. C., Chan M. Y., Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microbial Drug Resistance 2006 12 1 7 11 2-s2.0-33646053127 10.1089/mdr.2006.12.7
45. Ross D. L., Riley C. M., Aqueous solubilities of some variously substituted quinolone antimicrobials. International Journal of Pharmaceutics 1990 63 3 237 250 2-s2.0-0025201777 10.1016/0378-5173(90)90130-V
46. Barnard F. M., Maxwell A., Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser83 and Asp87. Antimicrobial Agents and Chemotherapy 2001 45 7 1994 2000 2-s2.0-0034959675 10.1128/AAC.45.7.1994-2000.2001 (Pubitemid 32591689)
47. Streicher E. M., Bergval I., Dheda K., Böttger E. C., Gey van Pittius N. C., Bosman M., Coetzee G., Anthony R. M., van Helden P. D., Victor T. C., Warren R. M., Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing. Antimicrobial Agents and Chemotherapy 2012 56 5 2420 2427 2-s2.0-84860161260 10.1128/AAC.05905-11